Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy.
about
Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Treatment Discontinuation and ...... Insulin as Third-Line Therapy.
@en
Treatment Discontinuation and ...... Insulin as Third-Line Therapy.
@nl
type
label
Treatment Discontinuation and ...... Insulin as Third-Line Therapy.
@en
Treatment Discontinuation and ...... Insulin as Third-Line Therapy.
@nl
prefLabel
Treatment Discontinuation and ...... Insulin as Third-Line Therapy.
@en
Treatment Discontinuation and ...... Insulin as Third-Line Therapy.
@nl
P2093
P2860
P50
P356
P1476
Treatment Discontinuation and ...... Insulin as Third-Line Therapy
@en
P2093
Hassan Behlouli
Michal Abrahamowicz
Zale B Rosenberg
P2860
P304
P356
10.1155/2018/4817178
P577
2018-03-11T00:00:00Z